Search Clinical Trials
Sponsor Condition of Interest |
---|
Adolescents Seeking COVID Vaccination (Teen COVID Vax)
National Institutes of Health Clinical Center (CC)
Ease Of Access To Covid Vaccine
Background:
Information is limited on the experience of children aged 15 to 17 who have or have not
been vaccinated against COVID-19. Research has assessed attitudes toward COVID-19
vaccination among adults and parents of teenagers. Few surveys have explored attitudes
among teens themselves.
Objective:
This... expand
Background: Information is limited on the experience of children aged 15 to 17 who have or have not been vaccinated against COVID-19. Research has assessed attitudes toward COVID-19 vaccination among adults and parents of teenagers. Few surveys have explored attitudes among teens themselves. Objective: This anonymous cross-sectional survey of a national sample US teens to find out about their experiences and attitudes on getting vaccinated for COVID-19. This study will be conducted in collaboration with a national firm (Qualtrics) responsible for the recruitment and data collection. Eligibility: People aged 15 to 17 years. Participants will come from urban, suburban, and rural areas in the United States. Factors such as race and gender will match US averages. Participants will only include subjects recruited by Qualtrics from their national panel of available respondents, who have agreed to be contacted by Qualtrics with opportunities to participate in surveys. Design: Participants will be contacted by email. The email will include a link to the survey. The emails will be sent only to people who agreed to be contacted about taking surveys. Participants will complete the survey online. It should take only 10 minutes. Questions will include the following: Have participants been vaccinated against COVID-19? Are they in the process of getting vaccinated? Do they want to be vaccinated? Have they had trouble getting vaccinated? If so, what kind of barriers did they face? What reasons have they considered for and against getting vaccinated? What have their personal experiences been with COVID-19? What is their primary source of information about COVID-19? Other questions will ask about: Household size. Employment of people in the household. How many people in the house have been vaccinated. The primary language spoken at home. The natural history survey will be anonymous. Participants will not be asked to give their names.... Type: Observational Start Date: Sep 2022 |
Lollipop COVID-19 Testing Study
University of Wisconsin, Madison
COVID-19
SARS CoV 2 Infection
COVID-19 Pandemic
This study will explore whether lollipop swabs are more acceptable and perform as well as
nasal swabs with PCR testing. The study will be open to enrollment for both children and
adults in the Madison community who have at least one COVID-19 symptom that has presented
in the last 5 days and who have... expand
This study will explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with PCR testing. The study will be open to enrollment for both children and adults in the Madison community who have at least one COVID-19 symptom that has presented in the last 5 days and who have not had a positive COVID-19 test for a previous illness within the past 3 months. Participants can expect to be in the study for the duration of the swabbing, approximately 10 minutes. Type: Interventional Start Date: Jul 2023 |
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Novavax
COVID-19
SARS-CoV-2 Infection
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3
different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will
enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive. expand
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive. Type: Interventional Start Date: Jul 2022 |
Povidone-Iodine Oral Rinse Study
University of Pennsylvania
COVID-19
This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded
clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing
SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label
trial, and all subjects will receive the... expand
This study is a two-arm, randomized, 2-phase study. Phase I will be double blinded clinical trial of the safety and efficacy of an antiseptic mouthwash solution on reducing SARS-CoV-2 load in COVID 19+ adult individuals. Phase II is designed as an open label trial, and all subjects will receive the active mouthwash. Type: Interventional Start Date: Feb 2022 |
Multimodal Investigation of Post COVID-19 in Females
Casa Colina Hospital and Centers for Healthcare
Post COVID-19
Cognitive Dysfunction
The purpose of this study is to investigate the effects of transcutaneous vagus nerve
stimulation (t-VNS) on Long Covid symptoms in females and to identify factors influencing
susceptibility and recovery-particularly in the cognitive domain, as over 80% of
long-haulers experience "brain fog". expand
The purpose of this study is to investigate the effects of transcutaneous vagus nerve stimulation (t-VNS) on Long Covid symptoms in females and to identify factors influencing susceptibility and recovery-particularly in the cognitive domain, as over 80% of long-haulers experience "brain fog". Type: Interventional Start Date: Mar 2022 |
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in...
ModernaTX, Inc.
SARS-CoV-2
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose
levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2
doses, 28 days apart, and 1 dose level of mRNA-1283 administered as a single dose to
healthy adults. expand
The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283 administered as a single dose to healthy adults. Type: Interventional Start Date: Mar 2021 |
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
American Society of Clinical Oncology
Neoplasms
Coronavirus
The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in
Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the
patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how
COVID-19 is impacting the delivery... expand
The American Society of Clinical Oncology (ASCO) Survey on Coronavirus 2019 (COVID-19) in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry collects both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic. Type: Observational [Patient Registry] Start Date: Apr 2020 |
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Baebies, Inc.
Influenza A
Influenza Type B
SARS CoV 2 Infection
RSV Infection
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2
Test to an FDA-cleared device. The study will utilize prospectively collected
de-identified nasopharyngeal samples obtained from both pediatric and adult populations
from subjects presenting with symptoms of respiratory... expand
The goal of this observational study is to compare the FINDER FLU A/B, RSV, SARS-CoV-2 Test to an FDA-cleared device. The study will utilize prospectively collected de-identified nasopharyngeal samples obtained from both pediatric and adult populations from subjects presenting with symptoms of respiratory illness. The main question it aims to answer are: • the study is to validate that the device intended use in terms that the device's performance meets the criteria for substantial equivalence with a predicate and satisfies the statutory criteria for Clinical Laboratory Improvement Amendments (CLIA) waiver. Type: Observational [Patient Registry] Start Date: Oct 2023 |
Community-engaged Optimization of COVID-19 Rapid Evaluation And TEsting Experiences
University of California, San Diego
COVID-19
COVID-19 Pandemic
Throughout the Coronavirus disease (COVID-19) pandemic, rates of COVID-19 have been
persistently high in San Diego County's central and southern communities near the United
States/Mexico border. These regions predominantly house Latino residents, the ethnic
minority community most impacted by COVID-19... expand
Throughout the Coronavirus disease (COVID-19) pandemic, rates of COVID-19 have been persistently high in San Diego County's central and southern communities near the United States/Mexico border. These regions predominantly house Latino residents, the ethnic minority community most impacted by COVID-19 in San Diego. In the Phase I project, University of California, San Diego (UCSD) partnered with San Ysidro Health (SYH) and the Global Action Research Center, to co-create and demonstrate the impact of a COVID-19 testing program in San Ysidro, one of the most impacted areas from COVID-19 in San Diego County. To date, the project tested >10,000 community members (92% Latino) and received requests to scale-out the testing program to additional primary care clinic sites. In this Phase III project, Community-engaged Optimization of COVID-19 Rapid Evaluation And TEsting Experiences (CO-CREATE-Ex) will extend work with the Phase I community and clinical partners to refine, specify, implement, and evaluate an implementation strategy bundle that optimizes COVID-19 testing, expanding beyond current polymerase chain reaction (PCR) testing to FDA-authorized COVID-19 rapid antigen testing. Type: Interventional Start Date: Aug 2023 |
Evaluation of Home Use COVID-19 Frequent Antigen Testing and Data Reporting
IDX20 Inc
COVID-19 Respiratory Infection
The current standard of care for diagnostic of SARS-CoV-2 infection involves sample
collection which is then prepared and measured via real time-polymerase chain reaction
(RT-PCR). This process is time consuming and dependent on expensive instrumentation and
trained technicians to perform both the... expand
The current standard of care for diagnostic of SARS-CoV-2 infection involves sample collection which is then prepared and measured via real time-polymerase chain reaction (RT-PCR). This process is time consuming and dependent on expensive instrumentation and trained technicians to perform both the sample preparation and assay. In many cases, sample turn-around times can take hours to several days. There are no established monitoring nationwide protocols for COVID-19 prevention of infection. Due to the lack of such protocols, this study will provide the proper experience to design a safe monitoring schema of asymptomatic cases of COVID-19. Self-testing using currently available RDT has a high specificity and relatively high sensitivity to identify individuals with a high probability of contagiousness. Therefore, we intend to use these RDT (Rapid diagnostic tests) for other use. There are several studies that point to the importance of the use of RDTs to monitor COVID-19 (3). The recent metadata indicate that the performance of the antigen test is crucial for obtaining good results to detect positive cases. We have already validated in the laboratory and using relevant clinical samples several different labels of antigen tests and we have compared them with already approved USA FDA antigen tests to confirm their performance prior to using them in this study. This project aims to monitor once a week the presence of SARS CoV-2 antigens using anterior nares (AN) swab self-process, executing the test and recording of the result, immediately after. The lack of affordable diagnostic tests which can detect the presence of SARS-CoV-2 in the general population which can give near real-time results is one critical missing control intervention in USA for the control of the pandemic and the spread of this disease. As public health restrictions begin to ease and people return to normal activities, while the COVID-19 pandemic is still a threat, a rapid diagnostic assay that does not require the sophisticated laboratory equipment and techniques could provide a significant advantage to screen asymptomatic individuals. The routine use of such rapid tests is a key element to show efficacy of protocol. We adjusted to once a week testing based on the medium to low risk of the elderly population of this study. The list of rapid nucleoprotein tests utilized in the current study are: NETO Corona test, Novir INSTA-TM COVID-19 Rapid Antigen test, COVICHEK COVID-19 Ag Test, SpectraBiotech COVID-19 track antigen test, Blandford Biotech AS-15™ Rapid Antigen Detection Kit SARS-CoV-2 Test (Colloidal Gold Method), Abbott BinaxNow tests. BACKGROUND The SARS-CoV-2 Direct Antigen Rapid Test ("Lateral flow") is an immunoassay developed for the qualitative detection of SARS-CoV-2 viral particles/secreted protein in anterior nasal swabs and/or saliva samples from both asymptomatic and suspected participants with COVID-19 infection. Lateral flow strips are printed with a monoclonal antibody that binds the signature SARS-CoV-2 viral particles/protein (Test line) and a control antibody (Control line) for quality control. A second monoclonal antibody is attached to gold nanoparticles (conjugate) and quencher buffer, and mixed with the nasal sample. The SARS-CoV-2 nucleocapsid protein attach to both antibodies resulting in a visual line on the test strip within 15 minutes. Prior experience in the detection of virus and viral proteins via antibody binding using lateral flow have been done through IDx20, Inc. The Housing Authority and the Public Health Department of the City of Chelsea will be overseeing this study. Type: Interventional Start Date: Dec 2021 |
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention...
Regeneron Pharmaceuticals
Immunocompromised
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab,
compared with placebo, in preventing symptomatic SARS-CoV-2 infection in
immunocompromised participants.
The secondary objectives of the study are:
- To evaluate the safety and tolerability of repeated SC... expand
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: - To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population - To characterize concentrations of casirivimab and imdevimab in serum over time - To assess the immunogenicity of casirivimab and imdevimab Type: Interventional Start Date: Oct 2021 |
Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
Lena Napolitano, MD
COVID-19 Pneumonia
The purpose of this study is to find out whether the drug uproleselan can help patients
with severe COVID-19 pneumonia. Investigators will study both the side effects of the
drug and assess if the drug will help patients recover more quickly and slow down the
progression of acute respiratory failure. expand
The purpose of this study is to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure. Type: Interventional Start Date: Nov 2021 |
Remote Monitoring of COVID-19 Positive Outpatients
Emory University
Covid19
This study seeks to evaluate how secondary data retrieved from remote physiological
monitoring performed during routine outpatient/at-home care periods can allow for the
discovery of novel physiomarkers that predict acute deterioration or hospitalization
among people testing positive for Coronavirus... expand
This study seeks to evaluate how secondary data retrieved from remote physiological monitoring performed during routine outpatient/at-home care periods can allow for the discovery of novel physiomarkers that predict acute deterioration or hospitalization among people testing positive for Coronavirus Disease 2019 (COVID-19). Type: Observational Start Date: Jun 2021 |
New Reusable Mask Design With Superior Filtration and Fit
Mayo Clinic
Covid19
Tuberculosis
Respiratory Viral Infection
This study will test the filtration, air leak, and breathability of a newly designed
fully washable mask developed by Dr. Nordell with the Mayo Clinic. This mask is theorized
to be a superior alternative to other respirators currently used when one-time-use N95
masks are unavailable. expand
This study will test the filtration, air leak, and breathability of a newly designed fully washable mask developed by Dr. Nordell with the Mayo Clinic. This mask is theorized to be a superior alternative to other respirators currently used when one-time-use N95 masks are unavailable. Type: Interventional Start Date: Apr 2021 |
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus...
BioAge Labs, Inc.
Covid19
The primary objectives of this study are to evaluate the safety, tolerability, and
efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented
COVID-19. expand
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19. Type: Interventional Start Date: Mar 2021 |
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
Susanna Naggie, MD
Covid19
The purpose of this study is to evaluate the effectiveness of repurposed medications
(study drug(s) in reducing symptoms of non-hospitalized participants with mild to
moderate COVID-19. Participants will receive either study drug or placebo. They will
self-report any new or worsening symptoms or medical... expand
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. This protocol was originally registered under NCT04885530. Per recent guidance on reporting master protocol research programs (MPRPs), a separate record for Arm A was created. Type: Interventional Start Date: Jun 2021 |
Addressing Cognitive Fog in Long-COVID-19 Patients
Eva Szigethy
Cognitive Impairment
Long COVID
This study will assess two options to help patients better manage the cognitive fog and
emotional distress that may be associated with having Long-COVID. Long-COVID is
post-COVID conditions or symptoms lasting more than four weeks after infection.
Clinicians from the UPMC Long-COVID Clinic leading... expand
This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID. Long-COVID is post-COVID conditions or symptoms lasting more than four weeks after infection. Clinicians from the UPMC Long-COVID Clinic leading this study are evaluating the utility of computer-based evaluation of COVID-related cognitive fog and the helpfulness of two intervention strategies to treat moderate cognitive impairment using a randomized trial. The two intervention strategies include 1) a standardized dosing of amphetamine/dextroamphetamine medication that has been used to improve cognitive fog; and 2) a digital behavioral tool with an embedded health coach that is used on a mobile phone. Type: Interventional Start Date: Apr 2023 |
COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2
University of Maryland, Baltimore
COVID-19
SARS-CoV2 Infection
This study aims to investigate the clinical performance characteristics of the novel
point-of-care, semi-quantitative test for SARS-CoV-2 in the Emergency Department compared
to the gold standard (ELISA). expand
This study aims to investigate the clinical performance characteristics of the novel point-of-care, semi-quantitative test for SARS-CoV-2 in the Emergency Department compared to the gold standard (ELISA). Type: Observational Start Date: Aug 2022 |
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
SARS-CoV2 Infection
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19
vaccines in:
• People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
And
• People who have never had COVID-19 (SARS-CoV-2 infection). expand
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection). Type: Interventional Start Date: Jul 2021 |
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age...
Sanofi Pasteur, a Sanofi Company
COVID-19 (Healthy Volunteers)
The primary objectives of the study were:
- To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each
study intervention group.
- To describe the safety profile of all participants in each age group and each study
intervention group up to 12 months post-last... expand
The primary objectives of the study were: - To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group. - To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection. The secondary objectives of the study are: - To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study intervention group. - To describe the neutralizing antibody profile at Day 181 (Cohort 1) or Day 202 (Cohort 2) and at Day 366 (Cohort 1) and Day 387 (Cohort 2) of each study intervention group. - To describe the occurrence of virologically-confirmed coronavirus disease (COVID-19)-like illness and serologically-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. - To evaluate the correlation / association between antibody responses to SARS-CoV-2 Recombinant Protein and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection. Type: Interventional Start Date: Sep 2020 |
Cardiovascular Implications of COVID-19
University of Texas Southwestern Medical Center
SARS-CoV 2
SARS Pneumonia
COVID-19
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Cardiac Complication
At the end of December of 2019, a series of patients in Wuhan, China were struck with a
mysterious respiratory infection. These isolated events have rapidly grown into a deadly,
global pandemic. This pandemic is caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2), which results... expand
At the end of December of 2019, a series of patients in Wuhan, China were struck with a mysterious respiratory infection. These isolated events have rapidly grown into a deadly, global pandemic. This pandemic is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which results in the Coronavirus Disease 2019 (COVID-19). For individuals infected with COVID-19, approximately 30% of the hospitalized cases are associated with cardiovascular complications. Data are emerging that individuals with pre-exiting conditions (like hypertension, diabetes, cancer, or medical issues related to the immune system) are most susceptible to complications related to COVID-19. Furthermore, individuals of certain racial and ethnic backgrounds (e.g. African American and Hispanic) are at a higher risk of death from COVID-19. Despite these emerging observations, it remains unclear who will develop the cardiovascular complications (acute myocardial injury with evidence of a myocarditis-like picture and cardiogenic shock) and what the long term sequelae of this disease will be for survivors of this infection after hospitalization. Thus, the goals of this project are to better understand the epidemiology of cardiac injury in acutely ill COVID-19 patients through deep cardiac phenotyping and identify the molecular profile of individuals most susceptible to cardiac injury from COVID-19. Type: Observational [Patient Registry] Start Date: Sep 2020 |
Smell in Covid-19 and Efficacy of Nasal Theophylline
Washington University School of Medicine
Covid19
Anosmia
Olfactory Disorder
Covid-19 Pandemic
SARS-CoV-2 Infection
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily.
Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and
prevalence using objective olfactory testing could be even higher.
We propose a phase II single-site, double-blinded, placebo-controlled... expand
Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher. We propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD. Type: Interventional Start Date: Mar 2021 |
Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness
University of Southern California
Housing
Covid19
Mental Health
Physical Health
Social Interaction
This study aims to understand the comparative effectiveness of two PSH models (PB-PSH and
SS-PSH) on quality of life and COVID-19 related health behaviors by following for 6
months a cohort of 800 PEH who have been placed in either PB (n=400) or SS (n=400). In a
natural observational experiment, participants... expand
This study aims to understand the comparative effectiveness of two PSH models (PB-PSH and SS-PSH) on quality of life and COVID-19 related health behaviors by following for 6 months a cohort of 800 PEH who have been placed in either PB (n=400) or SS (n=400). In a natural observational experiment, participants will complete 6 monthly mobile-based questionnaires exploring quality of life including physical, mental, social, and housing/environmental health, COVID-19 prevention practices (i.e., handwashing, social distancing, face covering), and past-30-day healthcare utilization. A sub-sample of 40 participants living in both PB-PSH and SS-PSH will be qualitatively interviewed longitudinally to help contextualize quantitative findings. Focus groups will also be conducted with providers of PSH and qualitative interviews will be conducted with other key stakeholders to understand perspectives on the challenges of implementing and sustaining COVID-19 related prevention practices while maintaining a continuity of care. Type: Observational Start Date: Jan 2021 |
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Quantinosis.ai LLC
Coronavirus
Covid19
This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with
novel coronavirus (COVID-19) infection. expand
This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection. Type: Interventional Start Date: Nov 2020 |
Prognostication of Recovery in Early Disorders of Consciousness After COVID-19
Massachusetts General Hospital
Covid19
Coma
Consciousness Disorder
The primary aim of this research proposal is to use multimodal metrics (e.g., clinical
data and advanced neuroimaging) in the early (i.e., acute hospitalization) phase of
recovery from COVID-19-related disorders of consciousness to predict outcome at 3, 6, and
12 months post-hospitalization. We aim... expand
The primary aim of this research proposal is to use multimodal metrics (e.g., clinical data and advanced neuroimaging) in the early (i.e., acute hospitalization) phase of recovery from COVID-19-related disorders of consciousness to predict outcome at 3, 6, and 12 months post-hospitalization. We aim to construct an algorithm that synthesizes the results of these metrics to help predict recovery. Type: Observational Start Date: Jul 2020 |
- Previous
- Next